Peptide therapy TikTok claims: what the science actually says
Quick answer
5-Amino-1MQ is a selective NNMT inhibitor studied in rodent models for its potential to increase NAD+ availability and reduce adiposity, but no human clinical trial data has been published as of 2024. The creator is apparently combining it with Retatrutide, a GLP-1/GIP/glucagon receptor tri-agonist that showed significant weight loss in Phase 2 trials, making any attribution of fat loss to 5-Amino-1MQ scientifically uninterpretable. Both compounds exist in a regulatory gray zone and should only be used under qualified medical supervision with appropriate informed consent.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @connorgettingcheddar actually say?
The creator claims that 5-Amino-1MQ works by suppressing an enzyme he vaguely describes as "NAD or something," which he says puts the body into an energy-burning mode and "supercharges" mitochondria to accelerate fat loss. He's stacking it with something he calls "Ratatouille" — likely Retatrutide, a GLP-1/GIP/glucagon triple agonist peptide — and reports higher energy levels and faster weight loss compared to a previous Retatrutide-only cycle.
Credit where it's due: he does frame this as personal experience rather than universal advice. But the mechanism he describes is garbled enough to mislead anyone who takes it at face value, and the stack he's casually running is not something to replicate based on a TikTok anecdote.
Does the science back this up?
Partially, but the mechanism explanation is a mess. 5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), not NAD itself. This distinction matters.
NNMT is an enzyme that methylates nicotinamide, effectively diverting it away from NAD+ synthesis. When NNMT is overexpressed, particularly in adipose tissue, it suppresses NAD+ levels and reduces cellular energy expenditure. 5-Amino-1MQ blocks NNMT, which in theory allows NAD+ to accumulate, activating sirtuins and potentially boosting mitochondrial metabolism.
A 2021 study by Neelakantan et al. in Nature Communications showed that NNMT inhibition with a related compound reduced adiposity in diet-induced obese mice without caloric restriction. Romanelli et al. (2021, Journal of Medicinal Chemistry) characterized 5-Amino-1MQ specifically as a potent NNMT inhibitor with favorable pharmacokinetics in rodents. The mitochondrial upregulation angle has some mechanistic basis. But all of this is preclinical. There are no published human clinical trials on 5-Amino-1MQ as of 2024.
What did they get wrong (or right)?
The creator got the general direction right but the enzyme wrong. He says it suppresses "NAD or something" — it suppresses NNMT, the enzyme that degrades the precursor to NAD+. Saying it suppresses NAD is essentially backwards from what the mechanism actually does.
The "overclock your body cells" and "supercharge mitochondria" framing is colorful but not inaccurate in spirit. NNMT inhibition does appear to increase energy expenditure at the cellular level in animal models. That part tracks.
What he got wrong more seriously: describing this stack as if the results are attributable to 5-Amino-1MQ. He's running it alongside Retatrutide, a peptide that mimics three separate gut hormones and has shown significant weight loss effects in Phase 2 trials (Jastreboff et al., 2023, New England Journal of Medicine). Crediting 5-Amino-1MQ for faster fat loss when Retatrutide is in the picture is not a controlled observation. It's a confounded anecdote.
What should you actually know?
5-Amino-1MQ is a research chemical with zero human trial data published. The rodent studies are legitimately interesting, and the NNMT pathway is a real area of metabolic research. But interesting preclinical data has failed to translate to humans countless times.
Retatrutide, whatever the creator is calling "Ratatouille," is a different story. It has actual Phase 2 human data showing roughly 17% body weight reduction over 24 weeks (Jastreboff et al., 2023, NEJM). If someone on that peptide also reports faster fat loss, Retatrutide is the far more likely driver.
The stack itself raises real questions. Combining an experimental NNMT inhibitor with a powerful triple GI hormone agonist has no published safety data whatsoever. Any reported "higher energy" could reflect Retatrutide's metabolic effects, a placebo response, or something else entirely. This is not a protocol to replicate from a TikTok video.
- 5-Amino-1MQ is not approved by the FDA for any use.
- NNMT inhibitor research is active but entirely preclinical in humans.
- Retatrutide is in clinical trials but not yet approved or legally prescribable as a compounded peptide in most contexts.
- Stacking experimental compounds without medical supervision carries unknown risks.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide therapy TikTok claims: what the science actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptide therapy TikTok claims: what the science actually says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
5-Amino-1MQ is a selective NNMT inhibitor studied in rodent models for its potential to increase NAD+ availability and reduce adiposity, but no human clinical trial data has been published as of 2024.
FormBlends verdict
5-Amino-1MQ is a selective NNMT inhibitor studied in rodent models for its potential to increase NAD+ availability and reduce adiposity, but no human clinical trial data has been published as of 2024. The creator is apparently combining it with Retatrutide, a GLP-1/GIP/glucagon receptor tri-agonist that showed significant weight loss in Phase 2 trials, making any attribution of fat loss to 5-Amino-1MQ scientifically uninterpretable. Both compounds exist in a regulatory gray zone and should only be used under qualified medical supervision with appropriate informed consent.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- 5-Amino-1MQ is a selective NNMT inhibitor studied in rodent models for its potential to increase NAD+ availability and reduce adiposity, but no human clinical trial data has been published as of 2024. The creator is apparently combining it with Retatrutide, a GLP-1/GIP/glucagon receptor tri-agonist that showed significant weight loss in Phase 2 trials, making any attribution of fat loss to 5-Amino-1MQ scientifically uninterpretable. Both compounds exist in a regulatory gray zone and should only be used under qualified medical supervision with appropriate informed consent.
- 5-Amino-1MQ inhibits NNMT, which increases NAD+ precursor availability. The creator said it suppresses NAD, which is the opposite of the proposed mechanism.
- Rodent studies (Neelakantan et al., 2021, Nature Communications) show NNMT inhibition reduced adiposity without caloric restriction, but zero human trials have been published.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- 5-Amino-1MQ inhibits NNMT, which increases NAD+ precursor availability. The creator said it suppresses NAD, which is the opposite of the proposed mechanism.
- Rodent studies (Neelakantan et al., 2021, Nature Communications) show NNMT inhibition reduced adiposity without caloric restriction, but zero human trials have been published.
- Retatrutide produced approximately 17% body weight loss in Phase 2 human trials (Jastreboff et al., 2023, NEJM), making it the far more probable driver of any fat loss in this stack.
- Running two experimental compounds simultaneously makes it scientifically impossible to attribute effects to either one. This is basic confounding, not a controlled observation.
- Neither 5-Amino-1MQ nor compounded Retatrutide are FDA-approved, and no published safety data exists for this specific combination.
- The NNMT pathway is a legitimate area of metabolic research, but interesting rodent data routinely fails to replicate in humans. Preclinical results are not clinical evidence.
- Anyone considering either compound should consult a licensed clinician and understand that personal anecdotes on TikTok, even well-intentioned ones, are not a substitute for controlled data.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
connorgettingcheddar · TikTok creator
15.2K views on this video
Peptide therapy TikTok claims: what the science actually says
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by connorgettingcheddar, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.